Roche Obtains CE Mark for First Companion Diagnostic To Identify Patients with HER2-Low Metastatic Breast Cancer Eligible for ENHERTU

Roche announced the approval of the CE Mark for the VENTANA® HER2 Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® may be considered as a targeted treatment.